Yaz and Yasmin Have Few Differences Despite Differences

Both Yasmin and Yaz are produced by Bayer healthcare and are currently known as fourth generation birth control pills. Unfortunately, there has been a lot of discussion on the side effects produced by both the medications. While Yasmin has been found to produce side effects like Yaz gallbladder disease, blood clots in the legs etc, the side effects from Yaz have been reported to be more severe in nature. Yaz lawsuits, Yasmin lawsuits and Ocella lawsuits are being reviewed throughout the United States for women who have suffered serious and potentially life-threatening blood clots, including a deep vein thrombosis (Yaz DVT), which forms in the deep veins of the legs, pelvis or arms.

A DVT or deep vein thrombosis is a type of blood clot that usually occurs in the legs or deep veins of the pelvis.  While it is possible to have a DVT with minimal symptoms, they usually cause extreme pain and swelling in the affected limb.  If the Yaz Deep Vein Thrombosis dislodges, it could travel to other parts of the body and cause a pulmonary emolism, heart attack or stroke.According to an August 2009 study published in the British Medical Journal,
birth control pills containing drospirenone, such as Yaz, Yasmin and Ocella, carry a 6.3 times increased risk of a first deep vein thrombosis or pulmonary embolism.  When compared to women taking some other types of oral birth control, the increased risk was nearly four times more among users of Yaz, Yasmin and Ocella.

The FDA announced that the goal of aYaz and Yasmin safety review is to fully assess the risks and benefits of drospirenone-based drugs and that it will release new safety information to the public as it becomes available. Complaints have been filed on behalf of women who have suffered heart attacks, strokes, pulmonary embolism, deep vein thrombosis, gallbladder disease and other serious injuries after using Yaz, Yasmin, Beyaz or other drospirenone birth control pills.The FDA said it hasn’t yet reached a final conclusion that any of the products raise the risk of blood clots beyond that of other pills. According to a report from The Wall Street Journal, the FDA will convene an outside panel of medical experts on Dec. 8 to discuss the matter.